<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum</h1>

    <table>
      <tr><th>Ticker</th><td>ELAB</td></tr>
      <tr><th>Float</th><td>1.2 M</td></tr>
      <tr><th>IO</th><td>0.05%</td></tr>
      <tr><th>MC</th><td>1.7 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Press release summarizing small- and mid-cap movers: Trainerize (NASDAQ: TRNR) agreed to acquire Ergatta, raising TRNR's 2026 pro forma revenue guidance to >$30M with Ergatta expected to contribute >$10M and ~30% EBITDA; the deal caps enterprise value at $19.5M (50% tied to 2026 EBITDA ~ $4M) and is expected to be immediately accretive, targeting close in Q1 2026. Kraig Biocraft Laboratories (OTCQB: KBLB) activated the first wave of its 2026 production program and moved biomaterials to incubation ahead of a March multi-ton production run for recombinant spider silk. Theriva Biologics (NYSE: TOVX) out-licensed SYN-020 to Rasayana Therapeutics for a $300,000 upfront payment plus up to $38M in milestones and tiered single-digit royalties, with Rasayana assuming development costs. NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), filed 10 U.S. patent applications expanding EL-22 and EL-32 technologies into animal health and agriculture. The release is a paid editorial from 24/7 Market News and includes conflict disclosures.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>TRNR acquisition of Ergatta raises pro forma 2026 revenue guidance to >$30M and is expected to be immediately accretive</li><li>Ergatta expected to deliver >$10M in 2026 revenue with ~30% EBITDA margins</li><li>KBLB activated first wave of 2026 production program and initiated incubation ahead of a multi-ton scale-up production run</li><li>Theriva received $300,000 upfront and is eligible for up to $38M in milestones plus tiered royalties for SYN-020 out-license</li><li>NorthStrive (ELAB subsidiary) filed 10 U.S. patent applications expanding EL-22/EL-32 into animal health and agriculture</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>U.S. equity markets were pointing modestly lower at the time of the release</li><li>The article is a paid editorial and discloses that 24/7 Market News owns KBLB shares and was compensated</li><li>Forward-looking statements in the release are subject to risks and may not materialize</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/1e4b005d-a156-4514-b174-e91b9f9afc77" target="_blank">Original Article</a>
    </div>

    <div class="small">ELAB â€¢ TradersLink AI News</div>
  </div>
</body>
</html>